In case you missed it: July 5 to July 9
It was a very busy week for the Contemporary OB/GYN® team.
This week’s top articles included:
Surprise bills for childbirth
In addition to welcoming a newborn, parents may be unexpectedly billed for some hospitalization services, according to a research letter in JAMA Health Forum.
Novel antifungal treatment approved for vaginal candidiasis
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.
Visual Summary: Intrahepatic Cholestasis of Pregnancy
Refer to this visual summary from SMFM wherever you practice.
Meet the Board: Yalda Afshar, MD, PhD
Introducing Contemporary OB/GYN® Editorial Advisory Board member Yalda Afshar, MD, PhD.
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More
